Young people are increasingly using Wegovy and Ozempic

Use spiked in 2023, especially in females

3:29 PM

Author | Tessa Roy

vials in blue and yellow with syringe
Jacob Dwyer, Justine Ross, Michigan Medicine

Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States are surprisingly scarce. 

Now, a national study from Michigan Medicine shows that the use of these weight loss drugs is increasing rapidly in adolescents and young adults 12-25 years, especially females

Using 2020 - 2023 data from a national database representing 92% of pharmacies, the study team found a 594% increase in the monthly number of adolescents and young adults using Wegovy, Ozempic, and other glucagon-like peptide-1 receptor agonists (GLP-1RAs). 

For females, this increase was even more pronounced. 

The number of female adolescents 12-17 years using GLP-1RAs increased 588%, compared with 504% for male adolescents. 

The number of female young adults 18-25 years using GLP-1 RAs increased 659%, compared with 481% for male young adults. 

“This is the first study to document national trends in GLP-1RA dispensing in any population, including youth, said Joyce Lee, MD, MPH, the lead author of the paper. Lee is a pediatric endocrinologist and Professor of Pediatrics in the Susan B. Meister Child Health Evaluation and Research Center at the University of Michigan Medical School, the C.S. Mott Children's Hospital, and the Caswell Diabetes Institute. 

GLP-1RAs were approved for type 2 diabetes in 2005 and for weight management in 2014. 

Interest in these drugs surged in 2021 when semaglutide was approved for weight management in adults under the brand name Wegovy, and increased even further when Wegovy was approved for weight management in adolescents at the end of 2022. 

The report finds that endocrinologists, family medicine physicians and nurse practitioners were among the top prescribers of GLP-1 RAs to youth, suggesting that these clinicians should be the focus of efforts to ensure safe and appropriate prescribing. 

For example, because the biggest usage increase occurred in females, clinicians need to educate female patients about the potential safety risks of these GLP-1 RAs during pregnancy. 

The report also found that dispensing of Ozempic increased in youth, even though Ozempic is not approved in children for type 2 diabetes or weight management. 

“This finding suggests increasing off-label use of Ozempic for weight management in adolescents and young adults,” said Kao-Ping Chua, MD, the senior author of the paper and a member of the CHEAR Center.

Lee adds that some concerns have been raised about both the cost of GLP-1 RAs, which are expensive and meant to be taken over the longterm, as well as the unknown effects of these drugs on growth and development in youth. 

“The increasing use of GLP-1 RAs highlights the importance of understanding the long-term safety, efficacy, and cost-effectiveness of GLP-1RAs in adolescents and young adults,” she said.

Additional authors include Lauren Oshman, M.D., M.P.H., Dina H. Griauzde, M.D., MS.c.

The purchase of the IQVIA data was supported by the Susan B. Meister Child Health Evaluation and Research Center at the University of Michigan Medical School. This work was supported by grants P30DK089503 (MNORC), P30DK020572 (MDRC), and P30DK092926 (MCDTR) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Elizabeth Weiser Caswell Diabetes Institute at the University of Michigan. Dr. Chua is supported by grants R01DA057284-01 and K08DA048110-04 from the National Institute on Drug Abuse (NIDA). Dr. Sharifi’s research is supported by the National Heart, Lung, and Blood Institute (NHLBI) (R01HL151603) and the National Institute on Minority Health and Health Disparities (NIMHD) (R01MD014853) of the National Institutes of Health (NIH).

The Susan B. Meister Child Health Evaluation and Research Center, ElizabethWeiser Caswell Diabetes Institute, and the NIDDK NIDA, NHLBI, and NIMHD of the NIH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Lee reported receiving personal fees from GoodRx, Tandem Diabetes Care, and Sanofi outside the submitted work. Oshman reported stock investment from Eli Lilly (divested 2022) and Abbott (divested 2022) outside the submitted work. Griauzde reported receiving grants from NIH/NIDDK outside the submitted work. Chua reported receiving personal fees from the Benter Foundation and US Department of Justice outside the submitted work.

Paper cited: “Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023,” JAMA. DOI: 10.1001/jama.2024.7112


More Articles About: Diabetes Diabetes Counseling Diabetes Management Obesity & Weight Management
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories green background connecting to teal skull with brain inside both just outlines made out of felt
Health Lab
Can preventing inflammation improve heart and brain health?
Michigan Medicine research study aims to address inflammation’s role in diseases of the heart and brain.
photo of Dr. Eva Feldman
Research News
Dr. Feldman Named 2024 WIELD Trailblazer
Women Inspiring and Elevating Leadership in Diabetes (WEILD) named Eva Feldman, M.D., Ph.D., as a woman shaping diabetes and metabolism research and care.
University hospital building
News Release
Michigan Medicine to host live q&a discussion with obesity treatment experts
University of Michigan Health experts to discuss medications such as Wegovy, Ozempic, Zepbound and more
weight scale black white in exam room close up
Health Lab
Adding obesity experts to primary care clinics improves patients’ weight loss outcomes
A weight navigation program for primary care patients with obesity led to more use of proven weight management strategies and more weight loss
doctor in white coat with dark blue scrubs touching hand of patient in grey sweater and baseball cap in exam room
Health Lab
Neuropathy common, and mostly undiagnosed, among patients in this Michigan city
A research team, led by Michigan Medicine and in partnership with Hurley Medical Center, finds that nearly three-quarters of patients at a clinic in Flint, Mich., a community that is predominantly Black and socioeconomically disadvantaged, had neuropathy — of which 75% was undiagnosed.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Treating Diabetes & Weight: The Ozempic & Wegovy Effect
Today on The Fundamentals, our guest Dr. Martin Myers, Director of the U-M Elizabeth Weiser Caswell Diabetes Institute, discusses diabetes research in the context of Ozempic, Wegovy, and other drugs that are changing how people think about weight loss. You can learn more about Dr. Myers here, and you can follow the department of molecular and integrative physiology @UMPhysiology on X.